National Institute of Allergy and Infectious Disease, National Institutes of Health - FOR RELEASE Wednesday, Dec. 11, 1996 2:00 p.m. EST
Greg Folkers (301) 402-1663 - folkers@nih.gov
A clearer picture is now emerging of how factors intrinsic to the HIV-infected individual influence the rate at which HIV replicates in the person s body and how rapidly the patient will develop AIDS, says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID). These so-ca
National Institute of Allergy and Infectious Diseases, National Institutes of Health - EMBARGOED FOR RELEASE Wednesday, Nov. 27, 1996 5:00 p.m. EST
Greg Folkers (301) 402-1663 folkers@nih.gov
Transmission of HIV from a pregnant woman to her infant can occur when a woman has little or no detectable HIV in her blood and a relatively intact immune system, according to a new report by researchers supported by the National Institutes of Health (NIH). However, in the study a specific regimen of the drug zidovudin
National Institute of Allergy and Infectious Diseases; National Institutes of Health - EMBARGOED FOR RELEASE - Wednesday, Oct. 30, 1996 5:00 p.m. EST
Greg Folkers (301) 402-1663 folkers@nih.gov
In a one-year study of HIV-infected people, infusions of the immune system protein interleukin-2 ( IL-2 ) have resulted in dramatic and sustained increases in the primary immune system cells depleted during HIV infection, according to investigators at the National Institutes of Health (NIH). In the study, patients
National Institute of Allergy and Infectious Diseases, National Institutes of Health - EMBARGOED FOR RELEASE: Wednesday, Oct. 9, 1996
Greg Folkers
Three reports detailing the results of two large-scale HIV treatment studies, supported by the National Institute of Allergy and Infectious Diseases (NIAID), and an accompanying editorial, will appear in the Oct. 10, 1996 issue of The New England Journal of Medicine. Preliminary results of the two studies, known as ACT
National Institute of Allergy and Infectious Diseases National Institutes of Health - August 1996
Development of Topical Microbicides Worldwide, HIV is spread predominantly by heterosexual intercourse. Women face a significant risk for acquiring HIV because non-consensual sex and sex without condom use are common. In addition, their partners may engage in hidden high risk behaviors. Despite the risks confronting th
National Institute of Allergy and Infectious Diseases, National Institutes of Health - August 1996
Overview The number of women with HIV and AIDS in the United States is steadily rising. From 1985 to 1995, the proportion of reported U.S. AIDS cases occurring among women increased from 7 percent to 19 percent. HIV infection is now the third leading cause of death among women ages 25 to 44 and the leading cause of dea
National Institute of Allergy and Infectious Diseases, Naitonal Institutes of Health - Aug. 1, 1996
In HIV-infected people who develop active tuberculosis (TB), levels of HIV in the bloodstream increase five- to 160-fold, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID). The new findings, which build on previous work at NIAID and elsewhere, help explain why HIV-infected
National Institute for Allergy and Infectious Diseases National Institutes of Health - August 1996
An important focus of the National Institute of Allergy and Infectious Diseases (NIAID) is research devoted to the pathogenesis of human immunodeficiency virus (HIV) disease -- the complex mechanisms that result in the destruction of the immune system of an HIV-infected person. A detailed understanding of HIV and how i
National Institute of Allergy and Infectious Diseases National Institutes of Health - July 31, 1996
Public health programs promoting safe sex practices have contributed to a significant decline in the rate of new HIV infections among young men in Thailand , according to a study funded by the National Institute of Allergy and Infectious Diseases (NIAID). As reported in the Aug. 1, 1996 issue of the New England Journal
National Institute of Allergy and Infectious Diseases National Institutes of Health - July 24, 1996
To improve the safety of experimental AIDS vaccines based on live but weakened HIV, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have made a prototype of such a vaccine drug-susceptible so it can be eliminated from the body soon after use. We know how to attenuate HIV, but now we ve a
National Institute of Allergy and Infectious Diseases, National Institutes of Health - July 23, 1996
A NOTE TO PHYSICIANS Important Therapeutic Information on the Dosing of Clarithromycin for the Treatment of Disseminated Mycobacterium avium Complex (DMAC) Infection in HIV-Infected Patients PURPOSE OF THIS DOCUMENT This document provides information on the results of a clinical trial that compared the standard dose of
National Institute of Allergy and Infectious Diseases, National Institutes of Health - July 10, 1996
In a study at the National Institutes of Health (NIH), HIV-infected patients receiving antiretroviral drugs plus bimonthly, five-day infusions of interleukin-2 ( IL-2 ) reported feeling as well overall as individuals receiving antiretroviral therapy alone, despite the side effects during the infusions. Previously,
National Institute of Allergy and Infectious Diseases, National Institutes of Health - July 10, 1996
Treatment regimens for Mycobacterium avium intracellular complex (MAC), a life-threatening infection common among people with late-stage AIDS, should include not more than a 500 milligram (mg), twice-daily dose of clarithromycin, according to an ongoing study supported by the National Institute of Allergy and Infectiou
National Institute of Allergy and Infectious Diseases National Institutes of Health - July 9, 1996
In a multicenter clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), weekly doses of the drug fluconazole safely prevented certain common yeast infections and was not associated with adverse events or drug resistance. This is the first large, long-term study of HIV-infected wo
National Institute of Allergy and Infectious Diseases National Institutes of Health - July 9, 1996
New findings from the National Institute of Allergy and Infectious Diseases (NIAID) illuminate how the replication of the AIDS virus is tightly controlled by the interplay of positive and negative host factors. When in balance, these factors may keep the replication of HIV at a persistently low level, often for years,
National Institutes of Allergy and Infectious Diseases, National Institutes of Health - Monday, July 8, 1996
Laurie K. Doepel (301) 402-1663; Doepel@nih.gov
Currently, three dozen preventive HIV vaccines are being tested in small-scale clinical trials around the world. The National Institute of Allergy and Infectious Diseases (NIAID) is poised to move into large-scale efficacy trials as soon as a suitable product is identified, according to Jack Killen, M.D., director of N
National Institutes of Allergy and Infectious Diseases, National Insitutes of Health - Monday, June 10, 1996
Greg Folkers, (301) 402-1663, Folkers@nih.gov
A strong commitment to basic and clinical research is critical to the nation s preparedness for emerging and re-emerging diseases, says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Fauci will discuss the NIAID research approach to confronting new and newly r
National Institute of Allergy and Infectious Diseases, National Institutes of Health - May 23, 1996
Measuring the amount of HIV in the bloodstream is the best available method for predicting an HIV-infected person s risk of developing AIDS or dying, according to investigators of the Multicenter AIDS Cohort Study (MACS), a project of the National Institute of Allergy and Infectious Diseases (NIAID). John W. Mellors, M
National Institute of Allergy and Infectious Diseases, National Institutes of Health - May 1996
AIDS--acquired immune deficiency syndrome--was first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus (HIV). By killing or impairing cells of the immune system, HIV progressively destroys the body s ability to fight infections and
This information is designed to support, not replace, the relationship that exists between you and your doctor.